Veracyte Inc (NASDAQ:VCYT)
| 27.07 Delayed Data As of 3:21pm ET |  +0.25 / +0.93%Today’s Change | 14.85 Today|||52-Week Range 45.58 | -34.30% Year-to-Date |
Latest VCYT News | Press Releases
No recent news for Veracyte Inc.
Today’s Trading
| Previous close | 26.82 |
| Today’s open | 27.32 |
| Day’s range | 26.52 - 27.34 |
| Volume | 43,092 |
| Average volume (3 months) | 955,946 |
| Market cap | $2.1B |
Data as of 3:21pm ET, 12/08/2022
Growth & Valuation
| Earnings growth (last year) | -69.74% |
| Earnings growth (this year) | +49.10% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +86.85% |
| P/E ratio | NM |
| Price/Sales | 12.74 |
| Price/Book | 1.89 |
Competitors
| ---- | ||
| CLDXCelldex Therapeutics... | +1.66 | +4.48% |
| MYGNMyriad Genetics Inc | -0.08 | -0.41% |
| VIVOMeridian Bioscience ... | +0.01 | +0.03% |
Data as of 3:20pm ET, 12/08/2022
Financials
| Next reporting date | February 28, 2023 |
| EPS forecast (this quarter) | -$0.15 |
| Annual revenue (last year) | $219.5M |
| Annual profit (last year) | -$75.6M |
| Net profit margin | -34.42% |
Profile
Sector Health Technology |
Industry Medical Specialties |
No executives to display |
Corporate headquarters South San Francisco, California |
Forecasts
